Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary shares, par value NIS 0.10 per share
-
Shares outstanding
-
2,048,819,940
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
1,237,434
-
Shares change
-
-2,060,236
-
Total reported value, excl. options
-
$1,972,853
-
Value change
-
-$1,642,894
-
Put/Call ratio
-
0.22%
-
Number of buys
-
10
-
Number of sells
-
-8
-
Price
-
$1.60
Significant Holders of BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) as of Q2 2023
30 filings reported holding BLRX - BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share as of Q2 2023.
BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,237,434 shares
of 2,048,819,940 outstanding shares and own 0.06% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (260,976 shares), CITADEL ADVISORS LLC (212,769 shares), LPL Financial LLC (125,210 shares), Atria Wealth Solutions, Inc. (110,366 shares), RENAISSANCE TECHNOLOGIES LLC (98,710 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (84,098 shares), ENVESTNET ASSET MANAGEMENT INC (68,425 shares), PVG ASSET MANAGEMENT CORP (61,840 shares), GEODE CAPITAL MANAGEMENT, LLC (32,026 shares), and Geneos Wealth Management Inc. (23,500 shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.